Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.33 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29504578 | 1.00 | KDM1A (0.37) | KDM1AKCNH2KDM1BMCL1RCOR1 | |
| SCHEMBL15566427 | 0.82 | IDO1 (0.36) | MCL1ALDH1A1HTR7KDM4EGAA | |
| SCHEMBL645965 | 0.78 | ALDH1A1 (0.38) | MCL1MAP2K2MAP2K1ALDH1A1HTR7 | |
| SCHEMBL28247947 | 0.77 | KDM1A (0.41) | KDM1AKCNH2KDM1BRCOR1KIF11 | |
| SCHEMBL24194288 | 0.77 | KDM1A (0.34) | KDM1AKCNH2KDM1BRCOR1KIF11 | |
| SCHEMBL29488670 | 0.77 | KDM1A (0.37) | KDM1AKCNH2KDM1BRCOR1 | |
| SCHEMBL2111428 | 0.77 | KDM1A (0.37) | KDM1AKCNH2KDM1BRCOR1 | |
| SCHEMBL387936 | 0.74 | ALDH1A1 (0.40) | MCL1ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL4417489 | 0.74 | MAPT (0.40) | MCL1MAP2K2MAP2K1ALDH1A1HTR7 | |
| SCHEMBL12410552 | 0.74 | MCL1 (0.35) | MCL1MAP2K2MAP2K1ALDH1A1HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240151993-A1 | ELECTRON WITHDRAWING GROUP (EWG)-CONTAINING ORGANIC MOLECULES FOR IMPROVED OPTICAL PROPERTIES IN AR/VR COMPONENTS | META PLATFORMS TECHNOLOGIES, LLC | 2024-05-09 | — | — | US | disclosed |
| WO-2023242631-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LEGOCHEM BIOSCIENCES, INC. (KR) | 2023-12-21 | — | — | WO | disclosed |
| CN-117177970-A | Polycyclic derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-12-05 | — | — | CN | disclosed |
| US-20230312557-A1 | P2X3 MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2023-10-05 | — | — | US | disclosed |
| US-20230312557-A1 | P2X3 MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2023-10-05 | — | — | US | disclosed |
| EP-4103564-A1 | P2X3 MODULATORS | Bellus Health Cough Inc. (CA) | 2022-12-21 | — | — | EP | disclosed |
| WO-2022228490-A1 | POLYCYCLIC DERIVATIVE MODULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2022-11-03 | — | — | WO | disclosed |
| EP-3440078-B1 | HETEROCYCLIC GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD (IN) | 2022-09-28 | — | — | EP | disclosed |
| WO-2021161105-A1 | P2X3 MODULATORS | BELLUS HEALTH COUGH INC. (CA) | 2021-08-19 | — | — | WO | disclosed |
| US-10954229-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2021-03-23 | — | — | US | disclosed |
| WO-2008070692-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008067481-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008067481-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| WO-2008024725-A1 | AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024725-A1 | AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| EP-1007515-A1 | ARYLPYRIDAZINONES AS PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | Abbott Laboratories (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999010331-A1 | ARYLPYRIDAZINONES AS PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312557-A1 | P2X3 MODULATORS | P2RX3, P2RX2, P2RX6 | KDM1A 4134/4885KCNH2 1748/4885KDM1B 4156/4885 |
| US-20240151993-A1 | ELECTRON WITHDRAWING GROUP (EWG)-CONTAINING ORGANIC MOLECULES FOR IMPROVED OPTICAL PROPERTIES IN AR/VR COMPONENTS | AR, OR10J3, ESRRG | KDM1A 1930/4885KCNH2 134/4885KDM1B 1678/4885 |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | MAP3K2, MAP3K1, MAP2K2 | KDM1A 936/4885KCNH2 3284/4885KDM1B 949/4885 |
| US-10954229-B2 | GPR119 agonist compounds | GPR119, GPR84, GPR65 | KDM1A 2868/4885KCNH2 1015/4885KDM1B 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.